Received Aug 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | — |
PX received the vaccine at 15 YO, however they reported as "Guidelines are 16-18 but it was inadvertently given a year early; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 15-year-old male patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On 19-JUL-2023, the patient received the 1st dose of Menveo. On 19-JUL-2023, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: PX received the vaccine at 15 YO, however they reported as "Guidelines are 16-18 but it was inadvertently given a year early). The outcome of the inappropriate age at vaccine administration was not applicable. Additional Information: GSK receipt date 15-AUG-2025: The reporter had a patient receive Menveo at age 15. Their school requiring it to be received at age 16. Is patient needing another dose since it was received at 15 versus 16. That was correct. Guidelines are 16 to 18 but it was inadvertently given a year early, which led to Inappropriate age at vaccine administration. The parent does not want the patient to have to receive another one.